InflaRx (NASDAQ:IFRX) Earns "Sell (E+)" Rating from Weiss Ratings

Key Points

• InflaRx received a "sell (e+)" rating from Weiss Ratings, while HC Wainwright issued a "buy" rating with a price target of $6.00.
• The stock traded at $1.28 with an average price target of $6.20, reflecting mixed analyst opinions on its performance.
• InflaRx's latest quarterly earnings showed an EPS of ($0.24), meeting expectations and revealing revenue of $0.05 million for the quarter.

InflaRx (NASDAQ:IFRX - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by equities research analysts at Weiss Ratings in a research note issued on Tuesday,Weiss Ratings reports.

Separately, HC Wainwright began coverage on InflaRx in a research report on Tuesday, September 2nd. They issued a "buy" rating and a $6.00 price target on the stock. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, InflaRx has an average rating of "Moderate Buy" and a consensus price target of $6.20.

InflaRx Stock Performance

IFRX stock traded up $0.03 during mid-day trading on Tuesday, reaching $1.28. The company had a trading volume of 522,221 shares, compared to its average volume of 468,459. The company has a market capitalization of $85.59 million, a price-to-earnings ratio of -1.59 and a beta of 1.40. The firm has a fifty day simple moving average of $1.23 and a 200 day simple moving average of $1.14. InflaRx has a fifty-two week low of $0.71 and a fifty-two week high of $2.82.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.24). The company had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.02 million. As a group, analysts predict that InflaRx will post -1.04 earnings per share for the current year.

Institutional Trading of InflaRx

A number of institutional investors have recently modified their holdings of IFRX. XTX Topco Ltd purchased a new stake in shares of InflaRx in the first quarter valued at approximately $38,000. DAFNA Capital Management LLC acquired a new position in InflaRx during the first quarter worth $459,000. Cubist Systematic Strategies LLC raised its holdings in InflaRx by 33.9% during the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock worth $31,000 after purchasing an additional 7,616 shares during the last quarter. 683 Capital Management LLC raised its holdings in InflaRx by 26.8% during the first quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company's stock worth $2,678,000 after purchasing an additional 555,000 shares during the last quarter. Finally, Woodline Partners LP acquired a new position in InflaRx during the first quarter worth $766,000. 42.39% of the stock is currently owned by hedge funds and other institutional investors.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.